| Abstract |
[Abstract] Objective: To explore the difference and safety of amisulpride and risperidone in the clinical treatment of schizophrenia. Methods: 70 schizophrenic patients from May 2019 to may 2020 were selected and divided into two groups according to different treatment methods. 35 patients were treated with risperidone (recorded as control group) and 35 patients were treated with amisulpride (recorded as observation group). Results: before treatment, there was no significant difference in PANSS score between the two groups (P > 0.05). After treatment, the PANSS score of the observation group was lower, the quality of life score of the observation group was significantly higher, and the clinical total effective rate was higher than that of the control group (P < 0.05). Before treatment, there was no significant difference in prolactin, glucose and lipid metabolism indexes between the two groups (P > 0.05). After treatment, the IR, TG and RBI indexes of the two groups were higher than before treatment, and the RBI level of the observation group was lower than that of the control group (P < 0.05). There was no significant difference in BMI, IR, TG and TC indexes between the two groups after treatment (P > 0.05); There was no significant difference in the adverse reaction rate between the two groups (P > 0.05), and it disappeared after symptomatic treatment. Conclusion: Compared with risperidone, amisulpride has more significant clinical effect in the treatment of schizophrenia, which can improve the mental symptoms of patients, effectively improve the quality of life, ensure the safety of medication, and improve the prognosis of the disease.
|